Triana Biomedicines develops a molecular glue discovery platform that identifies small molecules to promote protein-protein interactions, enabling targeted protein degradation of disease-causing proteins. This approach addresses the challenge of treating approximately 85% of disease targets that are considered undruggable, particularly in cancer therapeutics.
Funding
$126M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Approximately 85% of disease-causing proteins are considered "undruggable" by traditional methods, presenting a significant challenge in developing effective therapeutics, particularly in areas like cancer. These targets lack accessible binding sites for conventional small molecule drugs, hindering therapeutic intervention.
Solution
Triana Biomedicines is developing a molecular glue discovery platform to address previously undruggable disease targets. Their approach identifies small molecules that induce or stabilize protein-protein interactions, enabling new therapeutic interventions. Specifically, these molecular glues promote interactions between a disease target and another protein, such as an E3 ligase, to alter the target protein's function or fate, often leading to its degradation. By harnessing the body's natural protein degradation machinery, Triana aims to create novel precision medicines for a wide range of diseases, with an initial focus on oncology. Their target-first and rational approach to molecular glue discovery allows them to consider a wide range of therapeutic applications for their products.
Target Audience
The primary target audience includes pharmaceutical companies and researchers focused on developing novel therapeutics for diseases with previously undruggable targets, particularly in oncology.
Features
- Proprietary protein:protein pairing engine to identify E3 ligases that are potential matches for challenging disease targets.
- Comprehensive glue discovery campaign covering diverse chemical spaces to identify new molecular glues.
- Target-first and rational approach to molecular glue discovery.
- Focus on targeted protein degradation (TPD) for groundbreaking new cancer medicines.